— Know what they know.
Not Investment Advice

XLRN NASDAQ

Acceleron Pharma Inc.
1W: +3.3% 1M: +2.9% 3M: +42.9% 1Y: +61.1% 3Y: +247.6% 5Y: +368.6%
$178.75
Last traded 2021-11-19 — delisted
NASDAQ · Healthcare · Biotechnology

Balance Sheet Trends

Total Assets
$932M +84.7% ▲
5Y CAGR: +44.8%
Total Liabilities
$77M +39.3% ▲
5Y CAGR: +15.8%
Shareholders Equity
$855M +90.2% ▲
5Y CAGR: +50.9%
Cash & Investments
$850M +97.0% ▲
5Y CAGR: +52.0%
Total Debt
$24M -26.1% ▼
Net Debt
-$647M -215.4% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2016FY2017FY2018FY2019FY2020
— Assets —
Cash$21M$100M$144M$238M$671M
Short-Term Investments$119M$177M$147M$194M$179M
Cash & ST Investments$140M$277M$291M$431M$850M
Net Receivables$3M$4M$7M$9M$26M
Inventory$0$0$0$0$0
Other Current Assets$4M$4M$8M$10M$17M
Total Current Assets$147M$285M$306M$450M$893M
Property, Plant & Equip.$5M$7M$7M$31M$30M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$95M$96M$0$22M$8M
Other Non-Current Assets$968K$1M$2M$2M$2M
Total Non-Current Assets$101M$104M$9M$55M$39M
Total Assets$248M$389M$315M$505M$932M
— Liabilities —
Accounts Payable$2M$1M$419K$2M$8M
Short-Term Debt$0$0$0$6M$7M
Deferred Revenue$541K$541K$0$0$0
Other Current Liabilities$14M$15M$18M$25M$45M
Total Current Liabilities$16M$17M$19M$33M$60M
Long-Term Debt$0$0$0$26M$0
Other Non-Current Liab.$2M$4M$4M-$4M$17M
Total Non-Current Liabilities$6M$7M$4M$22M$17M
Total Liabilities$22M$24M$23M$55M$77M
— Equity —
Common Stock$39K$46K$47K$53K$60K
Retained Earnings-$364M-$473M-$587M-$711M-$877M
Accumulated OCI-$425K-$895K-$560K$23K-$288K
Total Stockholders Equity$226M$365M$292M$449M$855M
Total Liabilities & Equity$248M$389M$315M$505M$932M
— Key Metrics —
Total Debt$0$0$0$33M$24M
Net Debt-$21M-$100M-$144M-$205M-$647M
Total Investments$213M$273M$147M$216M$187M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms